NCT07808151: Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 100 planned
- Started
- 30 Nov 2026
- Primary completion
- 30 Sep 2029
- Arms
- Dose Schedule 1 - Porustobart + Pembrolizumab, Dose Schedule 2 - Porustobart + Pembrolizumab
- Results
- None posted
- 8 Sep 2026: Trial registered